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Objectives: To determine the incidence of metformin-induced lactic acidosis during the
period  January 2014 to March 2017 in Aragon Healthcare Area III. To analyze the associated
clinical  and analytical factors and mortality.
Results: A total of 31 cases (61.3% males). Incidence: 79.76 cases/100,000 patients-year; mean
age  75.39 ± 9.34 years; 23 of them with levels of serum metformin (21.91 ± 15.52 mcg/ml);
milligrams/day  of metformin ingested: 1790.32 ± 499; 96.8% of cases in the context of acute
kidney  failure; 11 cases with a history of chronic kidney disease (35.5%); 12 required intensive
care (38.7%); 13 required purification treatment (41.9%; 3 hemodiafiltration, 10 hemodialy-
sis).  There was a significant correlation between daily milligrams of metformin ingested and
drug levels; levels of metformin; and peak creatinine, pH and lactate. Mortality was 25.8%.
There  were only significant differences between the deceased and survivors regarding the
duration  of stay and final creatinine. Multivariate logistic regression did not detect any study
variables associated with mortality.
Conclusions: The incidence in our healthcare area is higher than in other series, with a 25.8%
mortality  rate. Virtually all cases were in the context of prerenal acute kidney failure. In
29%  of cases, there was an overdose. Patients must be warned about the most common
lactic  acidosis-inducing situations, especially dehydration, if they continue taking the drug
at  such times.
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Incidencia,  factores  relacionados  con  la  presentación,  evolución  y
mortalidad  de  la  acidosis  láctica  asociada  a  metformina  en  el  área
sanitaria  de  un  hospital  de  tercer  nivel
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Acidosis  láctica
Fracaso  renal agudo
r  e  s  u  m  e  n
Objetivos: Conocer la incidencia de casos de acidosis láctica por metformina durante el peri-
odo enero de 2014 y marzo de 2017 en el Área Sanitaria III de Aragón. Analizar los factores
clínicos y analíticos asociados y la mortalidad.
Resultados: Treinta y un casos (61,3% varones). Incidencia: 79,76 casos/100000 pacientes-an˜o;
edad  media 75,39 ± 9,34 an˜os;  23 de ellos con niveles séricos de metformina (21,91 ± 15,52
mcg/mL); miligramos/día de metformina ingeridos: 1790,32 ± 499; 96,8% de casos en el con-
texto de fracaso renal agudo; 11 casos con antecedentes de enfermedad renal crónica
(35,5%); 12 requirieron UCI (38,7%); 13 requirieron tratamiento depurador (41,9%; 3 hemodi-
afiltración, 10 hemodiálisis) Existió correlación significativa entre: miligramos diarios
ingeridos de metformina y niveles del fármaco; niveles de metformina y: creatinina pico,
pH y lactato. La mortalidad fue del 25,8%. Solo hubo diferencias significativas entre los fal-
lecidos y los supervivientes respecto a la duración de la estancia y la creatinina final. La
regresión logística multivariante no detectó ninguna variable del estudio asociada con la
mortalidad.
Conclusiones: La incidencia en nuestra área sanitaria es más elevada que en otras series, con
25,8% de mortalidad. Prácticamente todos los casos en el contexto de fracaso renal agudo de
origen prerrenal. En un 29% de los casos hubo sobredosificación. Es necesario advertir a los
pacientes de las situaciones más frecuentes potencialmente inductoras de acidosis láctica,
especialmente la deshidratación, si siguen tomando el fármaco durante las mismas.
©  2018 Sociedad Espan˜ola  de Nefrologı´a. Publicado por Elsevier Espan˜a,  S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/Introduction
Metformin is currently one of the most prescribed drugs and
everything  suggests that in the future it will continue to
be  so.1 Thus it is particularly important to learn about the
adverse  effects of this drug. The possibility of inducing lactic
acidosis  stands out due to its severity, although with met-
formin  this complication occurs to a lesser extent than with
other  biguanides such as butformin and phenformin, being
removed  from the market because this problem.2 According
to  some series, the mortality of this complication is very high
(25–50%).2,3
However, the true incidence and practical significance
of metformin associated lactic acidosis (MALA) is being
debated in the medical literature. The cause–effect rela-
tionship  between metformin and lactic acidosis has been
questioned.4,5
In the present study we  intend to analyze what has been
the  incidence of MALA in recent years in our health area.
We  have also performed a descriptive analysis of our affected
patients  and the clinical and biochemical variables associated
to  an unfavorable outcome.
Material  and  methodsThe study was  preformed in the Health Area III of the Aragón
Region  which attends a population of 306,200 inhabitants. Theby-nc-nd/4.0/).
reference  hospital is Lozano Blesa University Clinical Hospital
of  Zaragoza (HCULB). Study period: from January 2014 to March
2017.
Source  of data: The Toxicology Service of the HCULB,
which exclusively perform determinations of metformin lev-
els in our health area, provided us with the list of the 23
patients who during the study period had metformin lev-
els  above 5 mcg/ml (therapeutic values: 1–2 mcg/ml), a limit
above  which it is considered toxic. In these patients it was
also  found that they met  the analytical criteria of lactic
acidosis: pH ≤ 7.35 with lactate level ≥5 mmol/l. The Clinical
Documentation Service of the HCULB provided us with an
additional  list of twelve diabetic patients taking metformin
with  discharge diagnostic codes compatible with lactic acid-
osis;  however in these cases the drug levels had not been
determined. After reviewing the medical records of these
patients,  it was found that five of them did not strictly full-
fill  the analytical criteria of MALA (pH ≤ 7.35 and lactate
level ≥5 mmol/l), so only seven out of the twelve patients
were  included in the study. The HCULB Pharmacy Service
provided us with the number of diabetic patients receiv-
ing  metformin treatment at two time points of the study
period,  June 2014 (10,636 patients) and January 2017 (12,510
patients). The arithmetic mean of the two values (11,573) was
used  to perform the calculations of incidence, expressed as
cases/100,000  patients-year, with a total sample of 30 cases of
MALA.
It  should be noted that shortly after completion of the
observational period, an additional case was  registered in
 0 1 9;
t
i
a
a
c
c
t
w
a
m
o
c
o
b
e
l
o
(
(
n
g
p
s
m
S
<
a
4
8
u
e
c
w
u
F
p
R
T
p
p
m
M
f
a
w
b
w
a
i
9
t
o
fn e f r o l o g i a. 2
he Nephrology Service, although it did not compute, it was
ncluded  for the analysis of the clinical and analytical vari-
bles  because the patient showed the highest levels of the
ctive  medication in the whole series (74.04 mcg/ml).
The  levels of metformin were determined by the liquid
hromatography-tandem method (high-performance liquid
hromatography coupled with triple-quad tandem mass spec-
rometry)  Agilent Technologies
®
.
The clinical records of all patients included in the study
ere  reviewed and the following clinical and analytical vari-
bles  were  collected: gender, age, Charlson comorbidity index,
etformin  daily intake (mg), metformin formulation (alone
r  in combination), number of active ingredients taken daily,
linical  features at admission, admission service, presence
f  Acute Kidney Failure (AKF), stage of AKF, etiology of AKF,
aseline  creatinine, baseline glomerular filtration rate (GFR)
stimated  by the CKD-EPI formula, peak of serum creatinine
evel  during admission, serum creatinine at discharge, days
f  hospital stay, need for admission to Intensive Care Unit
ICU),  need for renal replacement therapy (RRT), type of RRT
hemodialysis [HD]/continuous venovenous hemofiltration),
umber of sessions of RRT, pH, lactate, bicarbonate, anion
ap,  pCO2, prothrombin activity, potassium, hemoglobin,
lasma levels of metformin, final result of the admis-
ion (deceased/not deceased), cause of death, evidence of
etformin  overdose according to recommendations of the
panish  Agency of Medicines and Health Products6: GFR
30  ml/min, metformine is contraindicated; GFR between 30
nd  44 ml/min, maximum dose of 1000 mg/day; GFR between
5  and 59, maximum dose 2000 mg/day, GFR between 60 and
9,  maximum dose 3000 mg/day.
Statistical analysis: Nonparametric Mann Whitney test was
sed  to compare the variables of deceased vs survivors. Cat-
gorical  variables were  analyzed by the Chi square test; if the
onditions  required for the use of this test were  not met, it
as  replaced by Fisher’s exact test. Spearman coefficient was
sed  to analyze correlation between quantitative variables.
inally, a multivariate binary logistic regression analysis was
erformed  to select the variables associated with mortality.
esults
he incidence of MALA in our health area during the study
eriod  was  79.76 cases per 100,000 patient-year (61.15 cases
er  100,000 patients per year if we  only consider cases in which
etformin  serum levels were  available).
Our patients were  19 males (61.3%) and 12 females (37.8%).
ean  age was  75.39 ± 934 years; males were 75.58 ± 8.7 and
emales  75.08 ± 10.71 showing no significant difference in
ge.  Mean Charlson index was  6.77 ± 11.71 (males 6.84 ± 11.5,
omen  6.67 ± 22.1, again without statistical difference). Num-
er  of active drugs taken per day 10.19 ± 4.33 (males 9.58 ± 4.1,
omen  11.17 ± 4.7, no significant difference). Analysis of
ctive  ingredients prescribed show that 23 patients were  tak-
ng  an ACEI or ARA II, 22 were  on diuretics, 20 on statins, patients took NSAIDs, 5 patients were  taking ACEI/ARA II
ogether  with diuretic and NSAIDs. A 58% of patients were
n  metformin alone and the remaining 42% were  taking met-
ormin  in combination with another oral antidiabetic drug.3 9(1):35–43  37
The  most frequent dose of metformin was  850 mg every 12 h
in  10 patients. Six patients also received insulin. The aver-
age  daily dose of the drug was  1790 ± 499 mg.  The most
frequent clinical condition that led to the consultation was
nausea,  vomiting or diarrhea in 15 cases, followed by far from
chest  pain, fever, heart failure or hypoglycemia. These symp-
toms  motivated the consultation in two cases. The rest of
the  patients consulted for other reasons. Twelve cases were
attended  in the Nephrology Service, and 11 by the Inter-
nal  Medicine Service. The rest of patients were  admitted in
other  services: endocrinology, cardiology, psychiatry, general
and  the gastroenterology surgery received one case. Another
patient  was  treated only in the Emergency Room where he
died  and finally two patients were  admitted directly to the ICU,
where they also died. The average duration of hospitalization
was 11.23 ± 7.7 days.
Regarding the baseline renal function, the majority, 20
cases  (64.5%), had no history of chronic kidney disease (CKD),
with  abaseline GFR >60 ml/min. Three patients presented
stage 3a (GFR between 60 and 45 ml/min), 6 patients had stage
3b  (GFR between 44 and 30 ml/min) and finally 2 patients had
stage  4 (FG <30). Metformin was overdosed in 9 patients (29%
of  the patients); two in stage 4 in which metformin was  con-
traindicated, 6 cases in stage 3b and one case in stage 3a.
There  was  only one case of voluntary overdose and it was
the  one without deterioration of renal function. All other
patients  presented an episode of AKF, in 3 cases of parenchy-
mal  origin and in 27 it was  prerenal. In 25 cases (83.3%) the
AKF  reached stage III according to the KDIGO classification,
in  three cases it reached stage II and in the two remained in
stages  I.
A  total of twelve patients (38.7%) required admission to the
ICU,  and 19 cases (61.3%) did not require it. In 13 cases (41.9%) it
was necessary to use RRT and 18 cases (58.1%) did not need it.
Regarding the type of RRT, HD was  used in 10 cases (76.9%), the
number  of sessions was  2.3 ± 1.1 (range 1–5). Continuous ven-
ovenous  hemofiltration was  used in 3 cases (23.1%), and the
number  of sessions were  2.33 ± 1.53 (range 1–4). The duration
of  the HD sessions performed by the Nephrology Department
was  4 h. The duration of continuous venovenous hemofiltra-
tion  sessions in the ICU was around 6 h.
There  was a significant correlation between the daily dose
of  metformin and the serum levels of the drug (Fig. 1). Cor-
relation  was also found between the levels of metformin and
three  other variables: peak creatinine, pH and serum lactate
concentration (Figs. 2–4). Likewise, a correlation was  detected
between  the Charlson comorbidity index and the number of
active  drugs taken, as well as between the pH and the serum
potassium level.
A  total of 8 patients (25.8%) died during admission, com-
pared  to 23 (74.19%) who survived. Three patients died in
the  ICU, one of them due to asistolia refractory to resuscita-
tion  maneuvers, the second as a consequence of refractory
shock and multi-organ dysfunction and the third due to
sepsis.  Another patient died in the emergency department
due  to cardiorespiratory arrest without response to resusci-
tation  maneuvers, an underlying mesenteric ischemia was
suspected.  The rest of deaths occurred in the hospital ward.
One  of them due to palliative sedation in the context of dis-
seminated  neoplasia, another case due to acute pulmonary
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Fig. 1 – Correlation between the daily dose of metformin
and  the serum levels of the drug. r = 0.557, p = 0.009.
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Fig. 3 – Correlation between serum levels of metformin and
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Fig. 4 – Correlation between serum levels of metformin andpeak  creatinine. r = 0.491, p = 0015.
edema with respiratory failure, the third presented heart and
respiratory  failure with poor outcome and the last patient
presented a bilateral pneumonia with unfavorable evolution
leading  to sepsis and death.
Table 1 shows the comparison between the clinical and
analytical variables in patients deceased versus the survivors.
The  only significant differences were the final serum creati-
nine  level and the length of hospital stay. None of the variables
was  independently associated with mortality in the multivari-
ate  logistic regression analysis.
Discussion
Since its description in 1957 by Jean Stern, metformin has
become  one of the most prescribed drugs in the world.2 Cur-
rently,  it is estimated that 150 million patients are being
treated  with metformin worldwide for control of diabetes.1lactate.  r = 0.650, p = 0.001.
The study United Kingdom Prospective Diabetes Study showed
that  in type 2 diabetic patients the use of this drug was
associated with a decrease in mortality of all causes and of
cardiovascular origin as compared to those treated with sul-
fonylureas  or insulin.7 In addition to its hypoglycemic effect,
there  are many  other potential positive effects that have been
described  in recent years: cáncer,8 polycystic ovary,9 among
others.  It is also noteworthy the potential benefit against
aging  and neurodegenerative diseases even in non-diabetics,
a  fact that is currently being evaluated by a clinical trial.10
Therefore it would not be surprising that in the near future
the  use of this drug will increase even more.  In this con-
text  it is important to remember that metformin can also
produce  side effects, among which traditionally the possi-
ble  induction of lactic acidosis has been highlighted, which
in  some cases can be lethal. However, there is a debate in
n e f r o l o g i a. 2 0 1 9;3 9(1):35–43  39
Table 1 – Comparison of various variables in the group of deceased patients and survivors.
Deceased (n = 8) Not deceased (n = 23) Statistical significance
Age (years) 75.65 ± 8.35 74.63 ± 12.39 ns
Charlson index 7.13  ± 1.89 6.65  ± 1.67 ns
No. of drugs 10  ± 4.75 10.26  ± 4.29 ns
Dose  of metformin (mg/day) 1856 ± 499 1767.39 ± 507.8 ns
Basal serum creatinine (mg/dl) 1.06 ± 0.32 1.16 ± 0.52 ns
baseline eGFR(ml/min) 65.54 ± 19.82 62.40 ± 22.11 ns
Peak S. creatinine (mg/dl) 5.37 ± 2.81 6.07 ± 2.88 ns
Final S. creatinine (mg/dl) 4.54 ± 2.83 1.41 ± 0.76 0.001
pH 7.055 ± 0.23 7.151 ± 0.19 ns
Bicarbonate (mmol/l) 10.64 ± 7.54 12.51 ± 6.64 ns
pCO2 (mmHg) 31.75 ± 13.05 34.74 ± 14.70 ns
Anion GAP (mmol/l) 26.11 ± 6.6 26.9 ± 8.62 ns
Serum lactate (mmol/l) 10.33 ± 5.34 10.70 ± 5.76 ns
Prothrombin activity (%) 52.24 ± 29.9 71.35 ± 30.96 ns
Potassium (meq/l) 5.42 ± 1.22 5.91 ± 1.47 ns
Hemoglobin (g/dl) 10.83 ± 0.85 11.95 ± 2.22 ns
Hospital stay (days) 6.0 ± 8.7 12.74 ± 6.65 0.051
Need for ICU (%) 3  of 8 (37.5%) 9 of 23 (39.1%) 0.009
Need for RRT (%) 2  of 8 (25%) 11 of 23 (47.8%) ns
S. level of metformin (mcg/ml) 23.61 ± 16.61 24.24 ± 19.41 ns
Overdose 2 of 8 (25%) 7 of 23 (30.4%) ns
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he literature about the true incidence and importance of
his  problem. In a 2010 a Cochrane review concluded that
here  is no clear evidence that metformin is associated with
n  increased risk of lactic acidosis compared to other hypo-
lycemic  treatments.4
By contrast, in our study, the incidence of lactic acidosis is
ertainly  high, well above what has been reported in other pre-
ious studies, as shown by the data presented in Table 2,4,11–29
dapted and expanded from Lalau,5 so that in our opinion we
re  facing a real an important clinical problem that should
ot  be minimized. We did not obtain an average estimate of
he  patients treated with metformin during the entire study
eriod  because just collecting the data from the two specific
ates  of interval used was  already extremely laborious. There-
ore,  calculations were  made using the arithmetic mean of the
wo  values available. With this strategy of data collection for
stimation of the incidence, if there was  any bias, it would
ave  resulted in underestimation, because there could have
een  some case not detected in the search of the Clinical Doc-
mentation  Service due to a fault in coding. However, all cases
n  which metformin levels were determined are adequately
ollected and without possibility of error since there is only
ne  toxicology laboratory that centralizes these requests for
uantification of drug levels. Therefore, we believe that the
alues  obtained truly reflect the incidence of these events in
he health area of our hospital during the study period.
Metformin acts by inhibiting hepatic neoglucogenesis as a
onsequence of a relative energy deficit caused by the decrease
n  adenosine triphosphate produced in the mitocondria.30
ther important actions of the drug are mediated by the acti-
ation  of the enzyme AMPK, responsible for the pleiotropic
ffects of the drug.1,31 A beneficial effect on the intestinal
icrobiota has also been described.32 In the mitochondria,
he drug inhibits complex I of the respiratory chain by an
nknown  mechanism.30 It is better described the action on theive Care Unit; eGFR: estimated glomerular filtration rate.
inhibition  of the mitochondrial glycerol-3-phosphate dehy-
drogenase  enzyme that also causes a uncoupling of the
mechanism of cell respiration.33 In the presence of tissue
hypoxia, pyruvic acid produced as a final product of cyto-
plasmic  glycolysis is metabolized by the enzyme lactic acid
dehydrogenase to lactic acid (type A lactic acidosis). In the
absence  of hypoxia pyruvic acid is incorporated into the
mitochondria and is used as a substrate of the Krebs cycle
that  is coupled to the respiratory chain to produce adenosine
triphosphate by oxidative phosphorylation. The final effect of
biguanides  is similar to that produced by hypoxia (type B lactic
acidosis).34 In the case of metformin when used at therapeu-
tic  doses this effect is negligible, but when taken in excess,
intentionally, or at normal doses in a certain clinical context
(heart  failure, hypoxia situations, liver failure, dehydration,
CKD) and if there is associated with certain factors (radiologi-
cal  contrasts, drugs such as NSAIDs, ACE inhibitors or ARA II)
there is an increased risk of overdosage and induction of lactic
acidosis,35 especially if the clinical context is that of an AKF,
since  the drug is eliminated mainly by the kidney as unaltered
molecule.36
The debate also extends to the definition of such a clinical
situation. Some authors such as Lalau distinguish in clini-
cal  practice up to three different situations5: (1) the so-called
Metformin-unrelated hyperlactatemia – MULA, in the absence of
metformin  accumulation. It is especially true if blood levels
of  metformin are normal, below normal or even undetectable.
Lalau  maintains that this group is the most numerous and the
one  that carries worse prognosis. (2) Metformin-induced hyper-
lactatemia  – MILA. It refers to hyperlactacidemia caused only by
metformin. A typical case is the voluntary intoxication by met-
formin  in the absence of concomitant drugs. A similar case is
the acute accumulation of metformin due only to acute renal
failure.  (3) Metformin-associated hyperlactatemia – MALA – is the
most  complex case. The word “associated” means that the
40  n e f r o l o g i a. 2 0 1 9;3  9(1):35–43
Table 2 – Incidence of MALA published in various works.
Lucis (1987) 1972–1983 Canada 0 0/56,000
patients-year
Health and Welfare Canada
publication
Bailey (1988) 1976–1986 UK – 2.7/100,000 Research data
Bailey (1988) 1972–1977 Switzerland 2 6.7/100,000 Research data
Bailey (1988) 1972–1981 Sweden – 8.4/100,000 Research data
Wiholm (1993) 1977–1991 Sweden 16 1977–1981:
15/100,000
1981–1991:
2.4/100,000
Publications of the Swedish
Adverse  Effects Advisor
Committee
De Fronzo (1995) 1995–1996 USA 47 3/100,000 US FDA Publications
Misbin (1998) 1980–1995 Canada – 9/100,000 Cohort of Saskatchewan
Health  administrative
databases
Stang (1999) 1984–1992 France 73 2.9/100,000 Not specified
Chan (1999) January 1993–June
1995
Scotland 1 20/100,000 Retrospective cohort of
contraindications  for the
use  of metformin
Emslie-Smith 2000–2003 Scotland 10 30/100,000 Series of cases in the same
hospital
(2001) 1994–2005 UK – 3.3/100,000 Case-control analysis using
the  UK General Practice
Research  Database
Nyrienda (2006) 1993–2006 Australia 3 57/100,000 Patients from a population
database
Bodmer (2008) 2001–2005 Spain 13 2004: 138/100,000
2005: 76/100,000
Retrospective cases of
metabolic  acidosis in
hospitals
Kamber (2008) 1959–2009 All world – 4.3/100,0000 Data from 347 trials and
cohort  studies (n = 70,490
patients-year)
Almirall (2008) 2000–2008 Holland 16 47/100,000 Hospital data of serum
levels  of metformin
Salpenter (2010) 2007–2012 UK 35 10.37/100,000 Publications of the Clinical
Practice  Research Datalink
database
Van Berlo-van de
Laar  (2011)
2004–2012 UK – 7.4/100,000 A cohort of the Clinical
Practice  Research Datalink
(n  = 223,968)
Richy (2014) 1971–2014 Australia 152 2.3/100,000 Publications of the
Terapheutic  Goods
Administration
Eppenga (2014) 2013–2014 Italy 11 60/100,000 Publications of Emergency
Services  (n = 390,000)
Huang (2015) 2005–2009 New Zealand 10 19.46/100,000 Publication of the Hospital
of  the City of Auckland
(n  = 1,718,000 patient-year)
Mosconi (2015) January 2010–August
2014
Japan 30 5.95/100,000 Retrospective cohort study
(n  = 504,169 patients-year)
Haloob (2016) January 2014–March Spain 30 79.76/100,000 Case serie from healthcare
that  the correlation between both parameters is clear, as2017
induction of hyperlactataemia is a consequence (although to
a different degree, perhaps) of the accumulation of metformin
and  one or more  associated concomitant diseases. According
to  Lalau, this group would be less frequent than suspected
and  its prognosis would be better than that of MULA, grant-
ing  metformin a “protective” factor. The difficulty of applying
these  definitions, somewhat cumbersome in itself, also lies in
having available the determination of metformin levels in real
time, a fact that usually does not occur in routine practice.
In  any case and for the sake of simplicity, patients could be
divided  into two groups, those in which metformin is not
related  to the induction of lactic acidosis (the so-called MULA)área  III from the Aragon
Region
and  those in which the drug is the main responsible (MILA) or
share that responsibility with another series of concomitant
pathologies (MALA).
There  is also disparity between the studies on the
relationship between metformin levels and the degree of
lactic  acidosis, as the results between different studies are
discordant.37–41 However, the findings of the recent study by
Boucaud-Maitre et al. of large sample of patients showed
42we  have also reported in our study. The controversy also
extends  to recommendations for the dosage of the drug in
patients  affected by renal failure since they differ according to
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cientific societies and the opinion of some experts.43 In this
ine,  it is pertinent to recall the results of a Taiwanese study
hat  compared the mortality of a large cohort of CKD stage 5
atients treated with metformin vs untreated.44 The treated
roup  showed significantly higher mortality that paradoxi-
ally  was  not related to a higher incidence of lactic acidosis in
his group. The authors argue that the alteration of the mito-
hondrial  respiratory chain could be more  harmful in patients
ith  advanced chronic kidney disease, even without causing
actic  acidosis.
In  our study, we detected 29% of cases of overdosage
ccording to GFR. This is a feature that must be emphasized,
ecause it would be easily avoidable with an adequate pre-
cription,  for which the clinician who prescribes the drug
hould  previously request a blood biochemistry to determine
he  baseline renal function of the patient and make appropri-
te  adjustments in the dosage. In subsequent follow-up, renal
unction  should be monitored periodically as recommended
y  the guidelines. We  want to highlight that probably a high
umber  of MALA episodes detected in our study has been due
o  inadequate monitoring of dose prescribed relative to the
enal  function (in all cases except one that was  at the patient’s
ill).
Nevertheless, in defense of prescribing doctors, it can be
rgued  that recently there has been disagreement between
he  latest European guidelines, which are more  flexible for
reatment  with metformin in CKD45 and American guide-
ines,  which still contraindicate metformone administration
f  GFR is below 30 ml/min.46 In fact, until recently the data
heet  pointed out that metformin should not be used in
atients  with GFR <60 ml/min, but it was  often prescribed
elow the GFR limits. Recently the metformin data sheet has
een  modified by the European Medicines Agency.47 In the
ecent  Spanish medical literature there are also guides and
ecent  reviews on this subject.48,49
From our data, a typical case presentation could be an
lderly  patient with important and polymedicated comorbid-
ty,  in many  cases using drugs that can produce AKF, that
ndergoes dehydration due to gastrointestinal disorder but
he  patient continues to take metformin. The consequence
s  an episode of AKF stage III with metformin accumulation
f  elevation of the serum levels of the drug and an increase
n  lactate levels with reduction of the pH. Approximately 40%
f  the patients will require admission to the ICU and a sim-
lar  percentage need RRT illustrating the clinical severity of
he  situation, which in our patients caused a 25% of mortal-
ty.  The majority of patients were treated in the nephrology
nd  internal medicine services. Between the deceased and
he  survivors the only significant differences were  the final
erum  creatinine level, higher in deceased patients, and the
uration  of the hospital stay that was  lower in the deceased
nes.  No variable maintained its significance in the multi-
ariate  analysis, perhaps reflecting the limited sample size.
n  the aforementioned study by Boucaud-Maitre, the lactate
evel  was  independently associated with mortality.42
Metformin is a small molecule (129 Da) with a low protein
inding, so it diffuses freely through dialyzers and hemofil-
ers.  The limiting factor for its extracorporeal clearance is
ts  relatively large volume of distribution (1–5 l/kg) although3 9(1):35–43  41
this may  be reduced in the context of AKF. The justification
of  the RRT goes beyond the elimination of the drug from
the  organism since it also includes: (1) fast, predictable and
effective  correction of acidosis that is achieved with adminis-
tration  of bicarbonate, (2) improvement of hyperlactataemia,
(3) correction of the electrolyte abnormalities, and (4) renal
replacement therapy.36 Regarding the modality of the RRT to
be  used, a recent systematic review of the working group of
the  extracorporeal treatment of intoxications highlights the
superior  efficacy of hemodialysis as compared to continuous
techniques, so if the patient’s hemodynamic stability allows, it
is preferable to perform hemodialysis with bicarbonate in the
dialysis  fluid with exhaustive monitoring during the sesión.36
An elegant work recently published has shown that the dura-
tion  of the dialysis sessions should be prolonged to 5 or 6 h,
and  thereafter the levels of metformin and lactate should be
monitored  due to the possibility of rebound at the end of the
dialysis  session. There are no specific recommendations with
respect  to conductivity or other technical specifications.50
This study presents a series of limitations. First, it is retro-
spective,  which has led to biases in the selection of patients
and  errors in the collection and interpretation of data from
clinical  records, despite the attention paid when performing
this  task. Secondly, there is no control group, but it can argued
that  it would have been difficult to gather 31 cases from our
hospital  affected by lactic acidosis not attributable to MALA
during  the study period to be used as controls. Despite this, the
sample  size of our work is considerable and provides clinically
relevant  information.
In  conclusion, in this study we have detected a high inci-
dence  of MALA in our health area, although if we  apply the
definitions  of Lalau, a good part of our cases could be included
within  the group called MILA. Our incidence is much  higher
than  traditionally published, so we  believe that we  should
be  alert to detect and treat this clinical situation that may
have  serious consequences. We have had a 25% of deaths
in  our patients during admission. Base on the data extracted
from  our case series, and the substantial change issued by the
European  Medicines Agency in 2016,47 it is important to warn
patients  at the time of prescription of the harmful effects that
can  be produced if the treatment is continued if there is a risk
of  extracellular volume depletion with AKF with accumulation
of  the drug. Therefore it is important to consult with the doc-
tor  in situations of gastrointestinal disorders with vomiting
and  diarrhea. Likewise, it is also necessary to perform an ade-
quate  initial dosage, according to the patient baseline renal
function.
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